医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Human Longevity Announces the Acquisition of DoctorsForMe

2020年01月15日 PM10:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Human Longevity, Inc., an innovator in providing data-driven health intelligence and precision health to physicians and patients, announced today the acquisition of DoctorsForMe, Inc. The acquisition now allows clients of Human Longevity to access world-class physicians and services of Mass General, well trusted by patients worldwide as one of the best hospitals in the world.

David Karow, MD, PhD, President and Chief Innovation Officer of Human Longevity, commented, “DoctorsForMe uses Big Data and AI technologies to match a patient with a doctor that perfectly matches the patient’s specific need. The acquisition enables Human Longevity to provide a complete health intelligence solution for our clients from early disease detection to personalized treatment, all with the goal of living a longer, healthier life.”

ABOUT HUMAN LONGEVITY

Human Longevity provides unparalleled, precision health analytics to individuals through the Health Nucleus™ in La Jolla, CA. The Health Nucleus provides an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. This is provided via a multi-modal approach, integrating data from an individual’s whole genome, brain and body imaging via MRI, cardiac CT calcium scan, metabolic tests and more, using machine learning and artificial intelligence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005207/en/

CONTACT

Debbie Feinberg, VP of Marketing

Human Longevity, Inc.

858-864-1058

dfeinberg@humanlongevity.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genetron Health and InnoCare Team Up In Partnership To Accelerate the Development and Commercialization of Novel Drugs for Cancer Treatment
  • Hot Topics Recap: Coronavirus
  • Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
  • Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
  • Meiji Seika Pharma Co., Ltd:支持中国控制新型冠状病毒